The goal of the Administrative Core is to provide executive oversight and administrative support for all of the Pancreatic Cancer SPORE projects and cores. The Administrative Core will monitor the activities of all program components, ensure compliance with local and federal grant administration guidelines, and facilitate communication and collaboration among program members. Accordingly, the specific aims of the Administrative Core are as follows:
Specific Aim 1 : Facilitate intra- and inter-SPORE communication and collaboration. We will develop and maintain a dedicated website to provide real-time progress updates and contact information. In addition, we will establish bi-monthly working group meetings, monthly Steering Committee meetings, and an annual retreat to facilitate the exchange of ideas and the use of shared resources.
Specific Aim 2 : Provide administrative and fiscal oversight and support for all SPORE components. We will interact with Washington University's Grants and Contracts Office and the National Cancer Institute staff to prepare and submit annual progress reports and complete other projects as needed.
Specific Aim 3 : Coordinate all SPORE-related meetings. We will coordinate the External Advisory Board and Internal Advisory Board meetings, attendance at the annual SPORE workshop, and monthly SPORE Steering Committee meetings.
Specific Aim 4 : Coordinate SPORE Developmental Research Program administrative activities. We will solicit and coordinate the review of pilot project applications.
Specific Aim 5 : Coordinate the SPORE Career Enhancement Program. We will assist with recruiting and monitoring candidates and awardees in this program.
Specific Aim 6 : Assist investigators with preparing scholarly presentations, publications, regulatory documents, and all other SPORE-related products.
Specific Aim 7 : Enhance participation of underrepresented minorities in all SPORE activities.
Specific Aim 8 : Ensure that advocacy issues are properly addressed and included in all aspects of research with patient participants.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA196510-02
Application #
9321891
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Pati, Maria Laura; Niso, Mauro; Spitzer, Dirk et al. (2018) Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (?2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors. Eur J Med Chem 144:359-371
Brauer, David G; Ohman, Kerri A; Jaques, David P et al. (2018) Surgeon Variation in Intraoperative Supply Cost for Pancreaticoduodenectomy: Is Intraoperative Supply Cost Associated with Outcomes? J Am Coll Surg 226:37-45.e1
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Nywening, Timothy M; Belt, Brian A; Cullinan, Darren R et al. (2018) Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut 67:1112-1123
Brenot, Audrey; Knolhoff, Brett L; DeNardo, David G et al. (2018) SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion. Oncogenesis 7:32
Meyer, Melissa A; Baer, John M; Knolhoff, Brett L et al. (2018) Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat Commun 9:1250
Meyer, Melissa A; DeNardo, David G (2018) Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1. Immunity 48:621-623
Jiang, Hongmei; Xu, Mai; Li, Lin et al. (2018) Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Mol Cancer Ther 17:2144-2155
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Zhang, Daoxiang; Li, Lin; Jiang, Hongmei et al. (2018) Tumor-Stroma IL1?-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. Cancer Res 78:1700-1712

Showing the most recent 10 out of 25 publications